Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Cash from Financing Activities: 2019-2025

Historic Cash from Financing Activities for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $3.2 million.

  • Allogene Therapeutics' Cash from Financing Activities rose 376.58% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year decrease of 74.76%. This contributed to the annual value of $116.7 million for FY2024, which is 21.92% up from last year.
  • As of Q3 2025, Allogene Therapeutics' Cash from Financing Activities stood at $3.2 million, which was down 36.20% from $5.1 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Cash from Financing Activities registered a high of $108.6 million during Q2 2024, and its lowest value of $24,000 during Q2 2022.
  • Moreover, its 3-year median value for Cash from Financing Activities was $4.3 million (2023), whereas its average is $21.3 million.
  • As far as peak fluctuations go, Allogene Therapeutics' Cash from Financing Activities slumped by 99.46% in 2021, and later skyrocketed by 372,916.67% in 2023.
  • Quarterly analysis of 5 years shows Allogene Therapeutics' Cash from Financing Activities stood at $322,000 in 2021, then crashed by 85.71% to $46,000 in 2022, then soared by 236.96% to $155,000 in 2023, then spiked by 3,605.16% to $5.7 million in 2024, then spiked by 376.58% to $3.2 million in 2025.
  • Its Cash from Financing Activities was $3.2 million in Q3 2025, compared to $5.1 million in Q2 2025 and $14.0 million in Q1 2025.